Fact CheckerSign in

NCT05766007Completed

Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum

Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum: An Observational Cohort Study

Source: ClinicalTrials.gov · Last updated 7 Apr 2026

Brief summary (registry, in English)

The goal of this observational study is to learn about how long-acting injectable antipsychotic (LAIA) medications are affected by the changes that take place in the body during pregnancy, and how much an unborn baby is exposed to. The investigators are also interested in the amount of these drugs that enters into breastmilk and taken by babies during breastfeeding. In addition to their regular clinic visits to receive long-acting mental health medicine injection, participants will be invited for up to four study visits between day 2 and 14 after the injection. This will happen only once during pregnancy, and once during the breastfeeding period to collect a few drops of blood on special filter paper card from the finger using safety lancet. A few drops of breastmilk will also be collected. Immediately after delivery, a few drops of blood will be collected from the mother, umbilical cord and the baby heel. The investigators will use these samples to determine the amount of the drug in the body during pregnancy and compare this to the amount during the breastfeeding period. Additionally, every month during the third trimester, and during the first 3 months postpartum, participants will complete a questionnaire (using the Liverpool University Neuroleptic Side Effect Scale) to document how they are feeling. Clinical improvement will be documented by the primary care provider using the Clinical Global Impressions Scale. Findings from this study are expected to help healthcare providers to understand these drugs better so that they can make informed decisions about if and how to use these drugs in women who become pregnant or are breastfeeding.

Status (registry)
Completed
Study type
Observational
Enrollment
168 (actual)
First submitted
30 Jan 2023
Start date
1 Aug 2023
Primary completion date
21 Nov 2025
Lead sponsor
University of Liverpool
NCT number
NCT05766007

What you commit to

  • Study type: Observational
  • Participants enrolled: 168
  • From 1 Aug 2023 to the primary completion date, 21 Nov 2025
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Record of poor medication adherence.
  • Concurrent use of agents with known or uncertain interaction with study drug.

Other illness

  • Known hypersensitivity to study medication.

Other

  • Unable to understand study information.
  • Unable to provide written informed consent.
  • Personal circumstances will not allow completion of the schedule of study activities.
  • Currently experiencing severe pregnancy related complications

Who the study is looking for

  • Currently pregnant or breastfeeding.
  • If pregnant, plans to deliver within the facility.
  • Diagnosis of schizophrenia, mania or other psychoses.
  • Prescription of long-acting injectable antipsychotic (Risperidone, Paliperidone palmitate, Fluphenazine decanoate, Flupenthixol decanoate and Zuclopenthixol decanoate) as maintenance therapy started before study entry.
  • Scheduled to receive at least one injection before delivery (if pregnant) or before week 12 postpartum (if breastfeeding).
  • At least 18 of age at study entry.

Age in the registry: 18 years to 49 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Neuropsychiatric Hospital
Coordinator of this site? Confirm its status
AbeokutaNigeriaUnknown status
Neuropsychiatric Specialist Hospital
Coordinator of this site? Confirm its status
AkureNigeriaUnknown status
Obafemi Awolowo University Teaching Hospital
Coordinator of this site? Confirm its status
Ile-IfeNigeriaUnknown status
Federal Neuropsychiatric Hospital
Coordinator of this site? Confirm its status
KadunaNigeriaUnknown status
Federal Medical Centre
Coordinator of this site? Confirm its status
MakurdiNigeriaUnknown status
Federal Neuropsychiatric Hospital
Coordinator of this site? Confirm its status
YabaNigeriaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.